Skip to main content

Table 3 Exacerbations by drug cohort

From: Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD

Outcome

FSC cohort N = 925

AC cohort N = 1,924 (Reference group)

Unadjusted P-value

Adjusted HR and P-valuea(95% CI)

COPD exacerbation rate per 100 person-years, n

20.8

32.8

P = 0.04

0.58 P = 0.02 (0.38, 0.91)

 Requiring hospitalization /ED visit

2.2

7.2

P = 0.06

0.23 P = 0.03 (0.07, 0.84)

  1. KEY: AC – anticholinergic; CI – confidence interval; COPD – chronic obstructive pulmonary disease; FSC – fluticasone propionate-salmeterol 250/50; HR – hazard ratio.
  2. aAdjusted HRs obtained from Cox proportional hazards model controlling for age, region, Charlson comorbidity index score, number of short-acting beta-agonist cans, number of oral corticosteroid prescriptions, comorbid asthma or upper respiratory tract infection or lower respiratory tract infection, home oxygen therapy, and physician specialty on the index date.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us